Drugs / IN10028
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07596381 | May 2026 → Feb 2027 expected | cancer | InxMed (Shanghai) Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IN10028 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07596381 ↗ |
| Action | Inhibit | “more potent target inhibition” NCT07596381 ↗ |
| Route | Oral | “administered orally once daily (QD) continuously” NCT07596381 ↗ |
| Target | PTK2 | “focal adhesion kinase (FAK, also known as protein tyrosine kinase 2 [PTK2]) inhibitor” NCT07596381 ↗ |